Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients With FLT3 Mutant Acute Myeloid Leukemia
Clinical Lymphoma, Myeloma and Leukemia - United States
doi 10.1016/j.clml.2011.06.007
Full Text
Open PDFAbstract
Available in full text
Date
August 1, 2011
Authors
Publisher
Elsevier BV